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Background: The recently published SHIfT-trial confirmed the prognostic importance of heart rate as a risk factor in patients with chronic heart 
failure and reduced ejection fraction. However, it is not clear whether this prognostic importance is independent from the degree of beta-blockade, 
which might be an important criterion for patient selection for selective heart rate reduction by ivabradine. We therefore evaluated the prognostic 
power of heart rate at different levels of beta-blockade.
Methods: 642 chronic heart failure patients (17% female, age 59±13y, LVEF <40%) were subgrouped according to their beta-blocker medication 
in terms of percent recommended target dose: low: 6%-25% (n=236), intermediate: 26%-75% (n=243), high: >75% (n=163).
Results: 246 (38%) patients died after a follow-up period of 60months. We found a significant, positive interaction (p=0.026) between high 
heart rate and beta-blocker dosage showing that the power of heart rate >70 bpm to predict mortality increases as the beta-blocker dosage 
increases. Although in the total population high heart rate alone was not significantly associated with mortality risk, in the subgroup of patients with 
highest beta blockade high heart rate was a significant predictor of mortality (HR: 1.709 [1.061-2.754], p=0.0276), in contrast to patients with 
intermediate (HR: 1.151 [0.722-1.836], p=0.5536) and low beta-blocker dosages (HR: 0.992 [0.621-1.366], p=0.683).
Conclusions: The prognostic importance of elevated heart rate in patients with chronic heart failure and reduced ejection fraction depends on 
beta-blocker dosage. The prognostic power of heart rate was only apparent in patients with highest doses of beta-blocker medication. These findings 
confirn the importance of beta-blocker uptitration before initiation of selective heart-rate lowering agents such as ivabradin for improvement of 
outcome in chronic heart failure.
